Saturday 17 October 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024. In the quarter to June 2026, revenue grew 65.7%, EPS grew 66.7% and free cash flow grew 11.5%, each against the same quarter a year earlier.
13.58
1.14
−7.74%
Follow IOVA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z-Score |
(2.30) | 1.96 | 0.61 | — | — | — | — | — | — | — |
P/S ratio |
3.70 | 13.07 | 0.00 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(7.27) | (5.32) | (7.58) | — | — | — | — | — | — | — |
Beneish M-Score |
(2.46) | 121.48 | — | — | — | — | — | — | — | — |
P/Operating CF |
(18.56) | (29.27) | (22.68) | — | — | — | — | — | — | — |
P/B ratio |
1.40 | 3.02 | 3.26 | — | — | — | — | — | — | — |
Price to Tangible BV |
2.33 | 5.01 | 5.36 | — | — | — | — | — | — | — |
EV/Sales |
2.58 | 11.11 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
EV/Operating CF |
(2.25) | (5.16) | (4.49) | — | — | — | — | — | — | — |
EV/FCF |
(2.02) | (5.01) | (4.23) | — | — | — | — | — | — | — |
Quick Ratio |
2.74 | 3.21 | 2.54 | 5.16 | 5.65 | 11.47 | 7.86 | 32.54 | 15.15 | 33.51 |
Current Ratio |
3.20 | 3.74 | 2.79 | 5.24 | 5.69 | 11.59 | 8.10 | 33.02 | 15.56 | 34.12 |
Net Debt/EBITDA |
0.82 | 0.90 | 0.65 | 1.25 | 1.56 | 2.43 | 1.45 | 3.64 | 1.58 | 3.16 |
Debt/Assets |
0.00% | 0.11% | 0.13% | 0.15% | 0.13% | 0.00% | 1.23% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.29 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.77 | 0.95 | 0.81 | 0.74 | 0.67 | 0.79 | 0.80 | 0.82 | 0.85 | 0.32 |
Capex/Depreciation |
(0.84) | (0.29) | (0.75) | (0.95) | (1.88) | (15.57) | 3.07 | 3.19 | (1.06) | (1.68) |
| (55.50%) | (57.48%) | (81.91%) | (70.61%) | (53.55%) | (54.34%) | (51.64%) | (40.41%) | (58.94%) | (75.55%) | |
| (42.88%) | (44.02%) | (61.49%) | (54.93%) | (44.28%) | (46.64%) | (47.86%) | (38.85%) | (56.26%) | (73.75%) | |
ROIC |
(62.77%) | (63.73%) | (94.15%) | (865.83%) | (181.13%) | (604.97%) | 0.00% | 0.00% | (53,748.26%) | (7,483.12%) |
Return on Tangible Assets |
(89.79%) | (83.87%) | (142.52%) | (80.33%) | (65.86%) | (40.53%) | (69.09%) | (26.65%) | (64.77%) | (61.32%) |
Average Days of Receivables |
114.21 | 154.26 | 46.35 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
113.95% | 168.36% | 28,023.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
57.81% | 92.81% | 8,923.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.31 | 0.31 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
23.37% | 66.82% | 5,267.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.23 | 0.12 | 0.06 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(41.03%) | (17.57%) | (23.21%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(34.47%) | (16.97%) | (20.17%) | — | — | — | — | — | — | — |
Revenue per Share |
0.74 | 0.57 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.85) | (1.22) | (1.54) | (1.84) | (1.49) | (1.48) | (1.28) | (1.04) | (1.21) | (0.59) |
Capex per Share |
(0.09) | (0.04) | (0.09) | (0.13) | (0.24) | (0.34) | (0.06) | (0.01) | (0.02) | (0.03) |
Free Cash Flow per Share |
(0.94) | (1.26) | (1.63) | (1.97) | (1.73) | (1.82) | (1.33) | (1.05) | (1.22) | (0.62) |
Cash per Share |
0.83 | 1.12 | 1.19 | 2.96 | 3.29 | 4.55 | 2.47 | 4.82 | 2.23 | 3.01 |
Shareholders Equity per Share |
1.95 | 2.45 | 2.49 | 3.14 | 4.05 | 4.75 | 2.40 | 4.79 | 2.23 | 3.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.95 | 2.45 | 2.49 | 3.14 | 4.05 | 4.75 | 2.40 | 4.79 | 2.23 | 3.02 |
Free Cash Flow |
(336.24) | (364.05) | (384.11) | (313.18) | (265.51) | (251.92) | (165.81) | (102.45) | (79.74) | (34.19) |
Working Capital |
304.33 | 334.68 | 197.54 | 387.63 | 418.76 | 581.23 | 277.41 | 460.98 | 139.70 | 164.54 |
Capital Expenditures |
(33.84) | (11.07) | (22.29) | (20.42) | (37.57) | (46.79) | (6.92) | (1.20) | (1.03) | (1.52) |
Net Current Asset Value |
228.10 | 257.00 | 112.11 | 314.77 | 352.28 | 524.14 | 270.81 | 460.75 | 139.40 | 164.54 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
0.13 | 0.07 | 18.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | 0.35 | 0.26 | 0.21 | 0.20 | 0.05 | (0.26) | (0.14) | 0.40 | 0.38 |
Cash ROIC |
(33.77%) | (35.17%) | (44.38%) | (32.20%) | (23.56%) | (19.59%) | (27.17%) | (10.96%) | (27.41%) | (10.26%) |
Accounts Receivable Turnover |
3.47 | 4.72 | 0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
6.97 | 3.08 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
3.36 | 3.01 | 0.00 | — | — | — | — | — | — | — |
Average Days of Payables |
46.70 | 107.68 | 11,703.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
108.92 | 201.66 | 3,664.84 | — | — | — | — | — | — | — |
Average Receivables |
75.89 | 34.75 | — | — | — | — | — | — | — | — |
Average Payables |
24.83 | 30.32 | 29.86 | 26.99 | 20.45 | 14.54 | 9.15 | 1.99 | 1.05 | 0.91 |
Average Inventory |
51.60 | 30.95 | — | — | — | — | — | — | — | — |
Average Assets |
911.80 | 845.39 | 722.17 | 720.66 | 772.90 | 556.56 | 412.74 | 318.10 | 163.63 | 138.77 |
Average Common Equity |
704.49 | 647.51 | 542.12 | 560.65 | 639.07 | 477.73 | 382.58 | 305.83 | 156.19 | 135.47 |
Columns are period end dates